TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
蘇子佩Su, Tzu-Pei
- 協同主持人
- 執行臨床試驗年資 17 年 9 個月
-
chrystal0109@cgmh.org.tw
-
chrystal0109@cgmh.org.tw
發表文獻
8筆
1
Su TP, Huang JS, Chang PH, Lui KW, Hsieh JCH, Ng SH, Chan SC. Prospective comparison of early interim 18F-FDG-PET with 18F-FLT-PET for predicting treatment response and survival in metastatic breast cancer. BMC Cancer. 2021 Aug 10;21(1):908. doi: 10.1186/s12885-021-08649-z.
2
Ho KC, Toh CH, Li SH, Liu CY, Yang CT, Lu YJ, Su TP, Wang CW, Yen TC. Prognostic impact of combining whole-body PET/CT and brain PET/MR in patients with lung adenocarcinoma and brain metastases. Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):467-477. doi: 10.1007/s00259-018-4210-1.
3
Su TP, Ho KC, Wang CW, Lin CY, Liu CY, Yang CT, Yen TC. Prognostic Value and Clinical Impact of Pretreatment FDG PET in Pulmonary Lymphoepithelioma-Like Carcinoma. Clin Nucl Med. 2019 Feb;44(2):e68-e75. doi: 10.1097/RLU.0000000000002371.
4
Liu FY, Su TP, Wang CC, Chao A, Chou HH, Chang YC, Yen TC, Lai CH. Roles of posttherapy 18F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1197-1204. doi: 10.1007/s00259-018-3957-8.
5
Su TP, Lin G, Huang YT, Liu FY, Wang CC, Chao A, Chou HH, Yen TC, Lai CH. Comparison of Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Posttherapy Evaluation in Patients with Advanced Cervical Cancer Receiving Definitive Concurrent Chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2018 May;45(5):727-734. doi: 10.1007/s00259-017-3884-0.
6
Fang YD, Su TP, Chang CJ, Ho KC, Su M, Yen TC. Detecting Triple-Vessel Disease with Cadmium Zinc Telluride-Based Single-Photon Emission Computed Tomography Using the Intensity Signal-to-Noise Ratio between Rest and Stress Studies. Contrast Media Mol Imaging. 2017 Oct 15;2017:4945680. doi: 10.1155/2017/4945680.
7
Ho KC, Fang YD, Chung HW, Liu YC, Chang JW, Hou MM, Yang CT, Cheng NM, Su TP, Yen TC. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib. Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2155-2165. doi: 10.1007/s00259-016-3433-2.
8
Su TP, Cheng NM, Chuang HC, Chen CC, Lin C. Potential false-positive Meckel scan due to displaced kidney caused by recurrent retroperitoneal teratoma. Clin Nucl Med. 2014 Oct;39(10):e433-5. doi: 10.1097/RLU.0000000000000264.
